MA45672A - Anticorps multispécifiques dirigés contre cd40 et cd137 - Google Patents

Anticorps multispécifiques dirigés contre cd40 et cd137

Info

Publication number
MA45672A
MA45672A MA045672A MA45672A MA45672A MA 45672 A MA45672 A MA 45672A MA 045672 A MA045672 A MA 045672A MA 45672 A MA45672 A MA 45672A MA 45672 A MA45672 A MA 45672A
Authority
MA
Morocco
Prior art keywords
directed against
antibodies directed
multispecific antibodies
multispecific
directed
Prior art date
Application number
MA045672A
Other languages
English (en)
Inventor
Isil Altintas
Friederike Gieseke
Paul Parren
Rik Rademaker
Ugur Sahin
David Satijn
Original Assignee
Biontech Ag
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Genmab As filed Critical Biontech Ag
Publication of MA45672A publication Critical patent/MA45672A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
MA045672A 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137 MA45672A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016066840 2016-07-14

Publications (1)

Publication Number Publication Date
MA45672A true MA45672A (fr) 2019-05-22

Family

ID=59501399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045672A MA45672A (fr) 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137

Country Status (15)

Country Link
US (6) US11091557B2 (fr)
EP (1) EP3484922A1 (fr)
JP (3) JP7138630B2 (fr)
KR (3) KR102632202B1 (fr)
CN (2) CN117247458A (fr)
AU (2) AU2017296095C1 (fr)
BR (1) BR112019000512A2 (fr)
CA (1) CA3030636A1 (fr)
EA (1) EA201990293A1 (fr)
IL (1) IL264142B2 (fr)
MA (1) MA45672A (fr)
MX (1) MX2018015853A (fr)
SG (1) SG11201811431VA (fr)
UA (1) UA128304C2 (fr)
WO (1) WO2018011421A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63384B1 (sr) 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
CA3030636A1 (fr) 2016-07-14 2018-01-18 Genmab A/S Anticorps multispecifiques diriges contre cd40 et cd137
EP3496536A4 (fr) * 2016-07-20 2020-02-12 IGM Biosciences, Inc. Molécules multimériques fixant cd40 et leurs utilisations
WO2019025545A1 (fr) * 2017-08-04 2019-02-07 Genmab A/S Agents de liaison se liant à pd-l1 et cd137 et leur utilisation
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
SG11202002366VA (en) * 2017-09-19 2020-04-29 Mab Discovery Gmbh Agonistic cd40 antibodies
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
CN112867733B (zh) 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 抗cd137抗体及其应用
MA54139A (fr) * 2018-11-06 2021-09-15 BioNTech SE Formulation d'anticorps
EP3883600B1 (fr) * 2018-11-23 2025-03-12 Strike Pharma AB Conjugués bi-spécifiques
CA3128148A1 (fr) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Nouveaux anticorps se liant au cd40
CN111269315B (zh) 2019-06-19 2022-04-08 北京智仁美博生物科技有限公司 针对bcma的单克隆抗体
WO2021155916A1 (fr) * 2020-02-04 2021-08-12 BioNTech SE Traitement impliquant une vaccination d'antigène et des agents de liaison se liant à pd-l1 et cd137
WO2021156326A1 (fr) * 2020-02-04 2021-08-12 Genmab A/S Anticorps destinés à être utilisés en thérapie
US20230285555A1 (en) * 2020-04-17 2023-09-14 Dingfu Biotarget, Co., Ltd. Preparation specifically bound with cd137 and use thereof
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
CN112321700A (zh) * 2020-09-21 2021-02-05 四川省人民医院 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
KR20230169135A (ko) 2021-03-09 2023-12-15 젠맵 에이/에스 치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
WO2023174521A1 (fr) 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
AU2023269546A1 (en) * 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
CN119894928A (zh) * 2022-09-20 2025-04-25 科锐生物制品私人有限公司 拯救耗竭的免疫细胞的方法
EP4626446A1 (fr) 2022-12-01 2025-10-08 BioNTech SE Anticorps multispécifique contre cd40 et cd137 en polythérapie avec un anticorps anti-pd1 et une chimiothérapie
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025056180A1 (fr) 2023-09-15 2025-03-20 BioNTech SE Procédés de traitement faisant appel à des agents se liant à epcam et cd137 en combinaison avec des antagonistes de liaison à l'axe pd-1
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025179294A2 (fr) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Amplification d'ingénierie immunitaire
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CN100490895C (zh) * 2000-02-01 2009-05-27 泛遗传学公司 结合cd40的apc激活分子
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2478011C (fr) 2002-03-01 2013-05-21 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
DK1684805T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
SG148143A1 (en) 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
EP2236172A1 (fr) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Thérapie combinée avec des anticorps anti-CD20 et anti-CD40 pour le traitment de cancers des cellules B
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20080073725A (ko) 2005-11-01 2008-08-11 노파르티스 아게 항-ｃｄ40 항체의 용도
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
ES2702087T3 (es) 2007-06-21 2019-02-27 Macrogenics Inc Diacuerpos covalentes y sus usos
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2010015792A1 (fr) 2008-08-06 2010-02-11 Argenta Discovery Limited Composés hétérocycliques contenant de l'azote utiles comme modulateurs bifonctionnels des récepteurs m3 et des récepteurs bêta-2
WO2010047830A2 (fr) * 2008-10-24 2010-04-29 The Scripps Research Institute Agent permettant le traitement du virus de l'hépatite c
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
CN102448984A (zh) 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PL2506871T3 (pl) 2009-11-30 2017-03-31 Janssen Biotech, Inc Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
GB201003293D0 (en) * 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
WO2012149356A2 (fr) 2011-04-29 2012-11-01 Apexigen, Inc. Anticorps anti-cd40 et leurs procédés d'utilisation
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
HUE044633T2 (hu) 2011-10-27 2019-11-28 Genmab As Heterodimer fehérjék elõállítása
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
ES2744267T3 (es) 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
HUE048722T2 (hu) * 2013-07-05 2020-08-28 Genmab As Humanizált vagy kiméra CD3 ellenanyagok
PT3126381T (pt) 2014-04-01 2019-04-18 Ganymed Pharmaceuticals Ag Imunorrecetores e epítopos de células t específicos da claudina-6
ES2900898T3 (es) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
MX382549B (es) 2014-08-12 2025-03-13 Alligator Bioscience Ab Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.
RS63384B1 (sr) 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
US11008396B2 (en) 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
JP6845846B6 (ja) 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
RU2018139339A (ru) 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб Новые биспецифические полипептиды против cd137
SG11201810591VA (en) 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CA3030636A1 (fr) * 2016-07-14 2018-01-18 Genmab A/S Anticorps multispecifiques diriges contre cd40 et cd137
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
WO2018098370A1 (fr) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. Protéines de liaison à 4-1bb et leurs utilisations
WO2018187215A1 (fr) 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques à titre d'agoniste de 4-1bb
WO2018213747A1 (fr) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40

Also Published As

Publication number Publication date
WO2018011421A1 (fr) 2018-01-18
AU2017296095A1 (en) 2019-01-17
US20220033510A1 (en) 2022-02-03
EA201990293A1 (ru) 2019-07-31
US11084882B2 (en) 2021-08-10
IL264142B1 (en) 2025-04-01
KR20190028508A (ko) 2019-03-18
US11939388B2 (en) 2024-03-26
JP2019533466A (ja) 2019-11-21
US20230089969A1 (en) 2023-03-23
AU2017296095B2 (en) 2024-05-02
BR112019000512A2 (pt) 2019-04-24
CA3030636A1 (fr) 2018-01-18
US20200062853A1 (en) 2020-02-27
IL264142B2 (en) 2025-08-01
US11091557B2 (en) 2021-08-17
CN109641959A (zh) 2019-04-16
JP7138630B2 (ja) 2022-09-16
CN117247458A (zh) 2023-12-19
JP2022184871A (ja) 2022-12-13
NZ749274A (en) 2024-12-20
US20200247899A1 (en) 2020-08-06
KR102632202B1 (ko) 2024-02-02
CN109641959B (zh) 2023-08-22
US11440966B2 (en) 2022-09-13
US12077596B2 (en) 2024-09-03
JP2025186475A (ja) 2025-12-23
SG11201811431VA (en) 2019-01-30
UA128304C2 (uk) 2024-06-05
KR20240017129A (ko) 2024-02-06
US20210317225A1 (en) 2021-10-14
MX2018015853A (es) 2019-08-21
US20220064317A1 (en) 2022-03-03
AU2017296095C1 (en) 2024-11-14
EP3484922A1 (fr) 2019-05-22
IL264142A (en) 2019-02-28
AU2024205418A1 (en) 2024-08-22
JP7750808B2 (ja) 2025-10-07
KR20250097987A (ko) 2025-06-30

Similar Documents

Publication Publication Date Title
MA45672A (fr) Anticorps multispécifiques dirigés contre cd40 et cd137
IL287019A (en) Compositions and methods for internalizing enzymes
MA49823A (fr) Anticorps dirigés contre pd-l1
EP3333192A4 (fr) Anticorps dirigé contre le glypican-3 et application associée
MA50352A (fr) Anticorps multispécifiques
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
EP3341477A4 (fr) Nucléases crispr-cas9 modifiées
SG11201707663SA (en) Lyophilization of rna
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
GB201421083D0 (en) Enzyme inhibitors
GB201421088D0 (en) New enzyme inhibitors
EP3464592A4 (fr) Amplification omega
EP3280418A4 (fr) Inhibiteurs de btk azacarbazole
EP3037812C0 (fr) Électrode à enzyme
GB201421085D0 (en) New enzyme inhibitors
EP3268125A4 (fr) Détermination de cellules à l'aide d'amplification
DK3766582T3 (da) Cellekultur
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
EP3349794A4 (fr) Anticorps anti-cd115
EP3381941A4 (fr) Anticorps anti-epha4
DK3137616T3 (da) Forøgelse af cellulær lipid produktion ved forøgelse af aktiviteten af diacylglycerolacyltransferase og formindskelse af aktiviteten af triacylglycerollipase
EP3183364A4 (fr) Procédés d'amplification d'arn
DK3630968T3 (da) Enzymer til glycananalyse
IL270880A (en) Cell culture methods